Key result
Once-daily diltiazem SR reduces weekly angina episodes by ~68% versus placebo.
Why the study?
The efficacy of once daily sustained-release diltiazem at two dose levels in stable angina patients with positive exercise test was assessed to determine its prophylactic benefit.
Does once daily sustained-release diltiazem reduce angina episodes and improve exercise tolerance in patients with stable angina?
Population
182 stable angina patients with positive exercise test
Comparison
Once daily sustained-release diltiazem 200 mg and 300 mg vs placebo
Design
Placebo-controlled randomized trial
Follow-up
7 days
Authors
Loading...
Supports once-daily SR diltiazem for stable angina symptom control; extends evidence for sustained-release calcium-channel blockade.
RCT (n=182)
Does once daily sustained-release diltiazem reduce angina episodes and improve exercise tolerance in patients with stable angina?
Absolute Event Rate: 68% vs 15%
p-value: p=< 0.05
Once daily sustained-release diltiazem (200 mg and 300 mg) effectively reduces angina episodes and improves exercise tolerance in patients with stable angina.
Francès et al. (1995) conducted an RCT in Stable angina (n=182). Sustained-release diltiazem vs. Placebo was evaluated on Decrease in weekly angina episodes (p=< 0.05). Once daily sustained-release diltiazem (200 and 300 mg) decreased weekly angina episodes by 68% and 64% respectively, compared to 15% with placebo (P < 0.05).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: